Logo-jre

   
J Ren Endocrinol. 2022;8: e25072 | Published on: 2022 Dec 28. doi: 10.34172/jre.2022.25072

Mini-Review

Colchicine and the concepts of nephroprotection; a new feature of an old drug

Hamid Nasri * ORCID

Cited by CrossRef: 2

1- Nidorf S, Ben-Chetrit E, Ridker P. Low-dose colchicine for atherosclerosis: long-term safety. 2024;45(18):1596 [Crossref]
2- Animati F, Cappannoli L, Proietti S, Fracassi F, Montone R, Ierardi C, Aurigemma C, Romagnoli E, Paraggio L, Lunardi M, Bianchini F, Leone A, Trani C, Liuzzo G, Burzotta F. Colchicine in coronary artery and cerebrovascular disease: “Old skin for the new ceremony”. World J Cardiol. 2025;17(11) [Crossref]
3- Iqbal Lone W, Chand J, Kumar P, Garg Y, Ahmed Z, Mukherjee D, Goswami A, Momo H. Anãl J. Discovery of colchicine aryne cycloadduct as a potent molecule for the abrogation of epithelial to mesenchymal transition via modulating cell cycle regulatory CDK-2 and CDK-4 kinases in breast cancer cells. Bioorganic Chemistry. 2024;150:107581 [Crossref]